The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
ApexOnco Front Page
Recent articles
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
The group cans ZW171 after “on-target, off-tumour toxicity”.
As pivotal data approach, the French group pays $210m for ex-US rights.
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
Duality takes its Adam9-targeting conjugate into the clinic.
It’s a new term for biotech and its investors.
Pumitamig is the latest to be tested in first-line disease.
